Loading
Sarasota – Omeza LLC, Sarasota, recently announced it closed on the sale of $5 million of convertible notes to 22 current and six new investors.
The money will be used to finance commercial operations for the Omeza collagen matrix wound treatment kit. The kit is designed to generate more equitable access and better outcomes for patients, improve workflows and profits for care sites, and lower total cost of care.
“Our Pre-market Notification application is under substantive review with FDA, and we are raising capital to support the launch of our patent-protected Omeza collagen matrix Rx drug-device combination product,” Omeza Founder and CEO Tom Gardner says in a release.
With this sale, the transformational skin health company’s total investment now totals $13 million, all of it from individuals. The company's goal is to raise $20 million for the Series A capital raise. The Series A round likely will be the company’s first institutional round of funding.
Omeza is being advised on Series A by Westbury Group, Westport, Connecticut. This round of funding shows investors that the company has an established business idea and strategy.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
